about
Drug treatment for spinal muscular atrophy types II and IIITreatment for cramps in amyotrophic lateral sclerosis/motor neuron diseaseCreatine for treating muscle disordersCreatine for amyotrophic lateral sclerosis/motor neuron diseaseDrug treatment for spinal muscular atrophy types II and IIICreatine for amyotrophic lateral sclerosis/motor neuron diseaseCreatine for treating muscle disordersTreatment for familial amyotrophic lateral sclerosis/motor neuron diseaseDrug treatment for spinal muscular atrophy types II and IIICreatine for amyotrophic lateral sclerosis/motor neuron diseaseTreatment for familial amyotrophic lateral sclerosis/motor neuron diseaseCreatine for treating muscle disordersInduced Pluripotency and Gene Editing in Disease Modelling: Perspectives and ChallengesMitochondrial dysfunction in amyotrophic lateral sclerosis - a valid pharmacological target?Targeting the prodromal stage of Alzheimer's disease: bioenergetic and mitochondrial opportunitiesThe creatine kinase/creatine connection to Alzheimer's disease: CK-inactivation, APP-CK complexes and focal creatine depositsMnSOD deficiency has a differential effect on disease progression in two different ALS mutant mouse modelsReprogramming of HUVECs into induced pluripotent stem cells (HiPSCs), generation and characterization of HiPSC-derived neurons and astrocytesBeing PRO-ACTive: What can a Clinical Trial Database Reveal About ALS?The PRO-ACT database: design, initial analyses, and predictive featuresCreatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS.R+ pramipexole as a mitochondrially focused neuroprotectant: initial early phase studies in ALS.Could digital patient communities be the launch pad for patient-centric trial design?Redox modifier genes and pathways in amyotrophic lateral sclerosis.Magnetic resonance spectroscopy of regional brain metabolite markers in FALS mice and the effects of dietary creatine supplementation.Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases.Genetic heterogeneity of amyotrophic lateral sclerosis: implications for clinical practice and research.ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?Reduced oxidative damage in ALS by high-dose enteral melatonin treatment.A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosisNovel therapeutic strategies in Parkinson's disease.A review of creatine supplementation in age-related diseases: more than a supplement for athletes.Quantifying disease progression in amyotrophic lateral sclerosis.Induced pluripotent stem cells: applications in regenerative medicine, disease modeling, and drug discovery.A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS.Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial designClinical Measures of Disease Progression in Amyotrophic Lateral Sclerosis.Synchrotron radiation Fourier-transform infrared and Raman microspectroscopy study showing an increased frequency of creatine inclusions in the rat hippocampal formation following pilocarpine-induced seizuresA Prophylactic Role for Creatine in Hypoxia?Pre-morbid type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosis
P2860
Q24200270-9D283027-11D6-4963-893C-C78B9CE2B50FQ24200285-7C74EAED-B41C-4114-9E73-345D54D019A3Q24202243-4696D35A-B1E2-4FAA-A606-47B3B8914632Q24202577-36AB04CB-12F5-4A74-A12F-5F662F9B752FQ24234414-98862525-7DDF-4384-A7FF-3E5A2ABACC0BQ24234800-DD74BFF5-73BC-4143-8454-C654ECC2CC70Q24236598-51EA4071-8723-4588-9AFC-5CD652088D09Q24241570-115C91B6-8C24-465D-BFFC-13C0DC6C8170Q24241759-429A542D-460F-42FC-8CD4-08B552B62761Q24244631-7FA00B51-B348-494E-B1DB-6EFAC88C48A4Q24245711-B11DDC90-8EC9-4EFF-B22D-030868E3C604Q24246414-F36E85CE-87B2-48E9-A286-47137EBB052CQ26775061-C94C9895-BE57-4B12-B5FF-8490D6154BFCQ27013585-4227F27F-037A-4125-9BE5-5F0D3020458CQ27338799-5A79A2E0-F490-4D81-B662-4030998574BBQ28200789-E3440591-A6B5-45E1-A208-80135D3E1E0FQ28291510-FB4F10CD-55E3-4FD2-94E7-1690482753D3Q28544716-59A5102C-389F-4D4B-A9D1-9E188A798EF9Q28649394-C4BC323B-AC9E-4A55-827B-A1AA91BA51C2Q28651661-54D47C8E-C76F-447A-BB31-96BECDC2E35DQ30440341-3EBCE821-FCC0-491A-8930-E612C2FBD727Q30445597-4B469599-528C-40F7-9FD7-6B07A1B9E6F4Q33689485-8EEA6728-F3E9-4DAF-8DDC-59176C12FBD8Q33742737-DA02F48C-0091-49CD-B2C9-72AE54682DF2Q33757934-3A24D733-5726-44AA-9D82-A4D52411D77DQ33917550-A4F0B6AF-6565-449F-81C1-ED50A9BBCDF2Q34401653-7741AF0E-E27D-46D0-A4FB-6EA99DDE26ECQ34554820-A0BB9A9F-96DD-4761-AE5C-F7023F465152Q34571459-6094CADD-944E-47E8-B807-5BED7B14D443Q34610044-0CAA7A34-82BD-4544-BDE0-747DB2DD5ED2Q34612832-6DA91F82-1883-4B81-855F-297240DCFB3EQ35005568-4BEB5704-EA77-4C99-8C47-9D342CAE435FQ35008605-7DCED6E3-47DB-472D-92D1-885749887C11Q35037783-95AA96A7-85BB-449A-98B1-4CCCE26497BEQ35162749-277FF833-9171-49C2-8834-87FAF703C8AAQ35210258-F6E5134D-B13F-469F-A325-F7BFB1C0733FQ35501852-0E532A49-F8C6-4248-93CC-E8C8C64C4B13Q35761665-C75A60FE-CEF9-48DA-9397-1A2569305F13Q35772902-713DEE0E-0688-4FD0-9372-410C8386CDCDQ35952241-EE5C3913-2412-414A-BF38-C738661AAAB2
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
A clinical trial of creatine in ALS.
@en
type
label
A clinical trial of creatine in ALS.
@en
prefLabel
A clinical trial of creatine in ALS.
@en
P2093
P1433
P1476
A clinical trial of creatine in ALS.
@en
P2093
A Pestronk
C Lomen-Hoerth
D MacDonald
D Schoenfeld
E Sorenson
H Mitsumoto
P304
P356
10.1212/01.WNL.0000142992.81995.F0
P407
P577
2004-11-01T00:00:00Z